Search

Displaying results 4731 - 4740 of 6198 in total
  1. Drug

    S-23

    go.drugbank.com/drugs/DB07419
    Experimental

    An androgen receptor modulator.

  2. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    Metrizamide is a solute for density gradient centrifugation offering higher maximum solution density without the problems of increased viscosity. It is also used as a resorbable, non-ionic contrast medium.

  3. Drug

    Ethylhexylglycerin

    go.drugbank.com/drugs/DB14557
    Investigational

    An emollient solvent with antimicrobial activity.

  4. Drug

    Mebhydrolin

    go.drugbank.com/drugs/DB13808
    Investigational

    Mebhydrolin is an antihistamine agent.[A275123]

  5. Drug

    Sipagladenant

    go.drugbank.com/drugs/DB17080
    Investigational

    KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822]

  6. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

  7. Drug

    Reteplase

    go.drugbank.com/drugs/DB00015
    ApprovedInvestigationalWithdrawn

    Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA.

    Products: RAPILYSIN 10 U IV ENJ. ICIN STERIL LIYOFILIZE TOZ ICEREN FLAKON, 2 ADET
  8. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.

  9. Drug

    GS-100

    go.drugbank.com/drugs/DB18337
    Investigational

    GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence

  10. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)."